GM, ITNS getting attention Stock - Investors Hangout MVP's

New Post Public Reply Private Reply Replies (2) Message Board

Oct 1, 2012 at 9:12 AM

GM, ITNS getting attention >>>

Stock Play ~ITNS

Good Morning Traders, most our attention the first part of this week will be on ITNS .012?s. Chart confirmed bottom play with solid news out this morning! We are sitting right above 52 week low with support. We expect major attention on ITNS throughout the week starting with this morning’s News. This could really make a big move once we break .02+

Charles Hensley, Ph.D., Inventor of Zicam(R) Cold Remedy, Creates Itonis Pharmaceuticals, Prepares to Announce Clinical Trial http://finance.yahoo.com/news/charles-hensley...ml

IRVINE, CA–(Marketwire – Oct 1, 2012) – Itonis, Inc. ( PINKSHEETS : ITNS ) and Charles Hensley, Ph.D., the inventor of the Zicam® Cold Remedy, and founding member of Itonis Pharmaceuticals, are pleased to announce that the organization of the first clinical trial of the recently announced over-the-counter and prescription homeopathic nasal spray for the treatment of nausea has commenced. The company plans to announce over the coming weeks full details of the double blinded, placebo-controlled clinical trial.

Dr. Hensley commented, “I’ve been working on the formulation for an over-the-counter, systemically active preparation delivered via a nasal spray for the alleviation of mild to moderate nausea. While there is considerable anecdotal indication that this preparation will be both safe and effective, we feel it is time for the rubber to meet the road in an Institutional Review Board controlled clinical study setting. We are actively organizing the study and look forward to announcing full details very soon.”

While the size of the market for anti-nausea related drugs and preparations is not exactly known, Itonis estimates it to be well in excess of $1 billion annually. There have been relatively few innovations within this product category over the past few years and the company believes the market is ripe for a new type of anti-nausea preparation to be available over-the-counter.

About Itonis, Inc. and Itonis Pharmaceuticals
Itonis Pharmaceuticals, a division of Itonis, Inc., is headed by Charles Hensley, Ph.D. This division’s mission is to create and market over-the-counter and prescription homeopathic products that better people’s lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of Geltech, LLC that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. He and his team plan to use the same methodologies to revolutionize the treatments of several other common ailments and other chronic diseases.

VIDEO CHART:

About Itonis Pharmaceuticals

Itonis Pharmaceuticals, a new division of Itonis, Inc., is led by Charles Hensley, Ph.D. This division’s mission is to create and market over-the-counter and prescription homeopathic products that better people’s lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of Geltech, LLC, the company that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States.

Please visit www.itonisholdings.com .

Itonis, Inc. is an Orange County, California based holding company. We were established in 2005 and are currently undergoing a company-wide transformation to embark upon an aggressive acquisition plan to purchase high growth entrepreneurial companies that have established themselves, or are expected to establish themselves as leaders in various market niches.

The company has relocated its headquarter offices to Orange County, CA in order to invigorate its operations and to implement company growth plans. A newly formed executive management team has been put in place, along with the appointment of a new board of directors. The transition is well underway.

The incoming management team brings decades of experience as successful business leaders and entrepreneurs who are dedicated to the planned vision of acquiring small companies with high growth potential. The executive team and its board of directors are well positioned to steer the company into a profitable future and are looking forward to the first of many exciting and successful years to come.